Precision BioSciences Set for Breakout with Key Gene Editing Trials
AI Prediction of Precision BioSciences, Inc. Common Stock (DTIL)
Precision BioSciences, a clinical stage gene editing company, is positioned for potential share price appreciation with upcoming clinical catalysts. The company's focus on gene-editing therapies for high unmet needs, specifically its PBGENE-HBV and PBGENE-DMD programs, offers significant upside potential.
Precision BioSciences is actively developing its proprietary ARCUS genome editing platform to create in vivo gene editing therapies targeting diseases with high unmet needs. Key programs include PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. Both programs are approaching significant clinical milestones, with expected data readouts that could serve as major catalysts for the stock. The company's strategic focus on these diseases, combined with a robust clinical development pipeline and a strong cash position to support operations through 2028, positions Precision BioSciences as a compelling investment in the biotech sector. These factors are expected to significantly influence the company's stock price in the near term.
DTIL Report Information
Prediction Date2026-03-23
Close @ Prediction$6.52
Mkt Cap161m
IPO Date2019-03-28
AI-derived Information
Recent News for DTIL
- Mar 12, 7:15 am — Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 12, 7:00 am — Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update (Business Wire)
- Mar 11, 7:01 am — Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program (Business Wire)
- Mar 10, 7:01 am — Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 (Business Wire)
- Mar 9, 5:35 pm — Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
- Mar 9, 4:15 pm — Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 (Business Wire)
- Mar 9, 7:01 am — Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event (Business Wire)
- Mar 2, 7:01 am — Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
- Feb 26, 6:00 pm — Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
- Feb 23, 10:35 am — Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
- Feb 18, 7:01 am — Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
- Jan 12, 7:01 am — Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy (Business Wire)
NDAPR (News-Driven AI Prediction Revision) events for DTIL
-
Jan 12, 7:06 amRevision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: Positive clinical advancements and strong financial position support continued bullish outlook.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest